Partnering with Boehringer Ingelheim at BIO-Europe 2024 Partnering with Boehringer Ingelheim at BIO-Europe 2024 Learn about partnering with Boehringer Ingelheim at BIO-Europe 2024 and how together we can accelerate innovation in human health
Generalized pustular psoriasis: Unmet needs Generalized pustular psoriasis: Unmet needs Dr Clerisme-Beaty and Dr Strober MD, PhD discuss the impact of living with GPP including unseen challenges and future management.
STOP Rabies: moving towards elimination STOP Rabies: moving towards elimination Rabies still kills thousands of people every year. However, rabies is 100 percent vaccine preventable. We contribute to eliminating the disease.
vaxxitek® hvt + ibd + nd vaxxitek® hvt + ibd + nd Bursal Disease-Marek's disease-Newcastle disease vaccine, serotype 3, live Marek's disease vector; the vaccine includes a diluent
Boehringer Ingelheim appointment to Board Managing Directors Boehringer Ingelheim appointment to Board Managing Directors Boehringer Ingelheim announces appointments to Board of Managing Directors
Spotlight on GPP Spotlight on GPP Emmanuelle Clerisme-Beaty, former Head of Clinical Development and Medical Affairs, Dermatology, answers some frequently asked questions about GPP.
Real stories, real impact: fighting rabies Real stories, real impact: fighting rabies The danger of rabies is often overlooked. The need for action, unseen. Learn how we can eliminate rabies through leveraging education and dog vaccinations.
New study paves the way for liver cirrhosis treatments New study paves the way for liver cirrhosis treatments The ADVANCE study will be the most detailed observational study of its kind providing a detailed analysis of liver health.
Who are we? Who are we? Started in 1885 by Albert Boehringer, this independent family-owned company has grown into a top contributor in Human Pharma and Animal Health.
Promising phase II results in chronic kidney disease Promising phase II results in chronic kidney disease Boehringer Ingelheim’s investigation of novel compound on top of standard of care empagliflozin shows promising results for chronic kidney disease
Life forward - Boehringer Ingelheim company brand Life forward - Boehringer Ingelheim company brand Life forward - Boehringer Ingelheim unveils its evolved company brand
Investment social engagements in Cowtribe veterinary startup Investment social engagements in Cowtribe veterinary startup Last-mile veterinary delivery social start-up Cowtribe first investment of Boehringer Ingelheim Social Engagements
cat dog flea allergy dermatitis cat dog flea allergy dermatitis Find out how you can identify and treat flea allergy dermatitis, one of the most common illnesses associated with a flea infestation.
Supporting Fundappas Supporting Fundappas Supporting Fundappas in Uruguay to improve quality of life of dogs and people.
Odile Bain Memorial Prize 2021 Odile Bain Memorial Prize 2021 Brilliant early-career scientists in parasitology recognized
Angels Initiative in South Africa Angels Initiative in South Africa Dr Stacey Rossouw explains how the Angels initiative is making a difference in South Africa and optimizing stroke care
See our locations See our locations We offer career development opportunities in over 170 locations across the world. Explore some of our featured locations.
EURORDIS Award EURORDIS Award EURORDIS has selected Boehringer Ingelheim for the first time as recipient of the prestigious Black Pearl Award 2020
Survodutide Phase III study weight loss Survodutide Phase III study weight loss Boehringer Ingelheim to advance survodutide into three global Phase III studies in obesity